News and Announcements
Xeophin Pty Ltd announces the launch of it’s Pre ICO & ICO raise using Blockchain technologies in Europe and Asia
- Published June 26, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Xeophin, a biotech company, is committed to the research, development and commercialisation of new and novel medical treatments
- Have appointed Dr.Goran Ando as Chairman of its Clinical Advisory Committee
- Have appointed ex-Chairman of Novo Nordisk, Dr.Goran Ando, as Chairman of its Clinical Advisory Committee
Xeophin is focused on imunomodulating technologies and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Xeophin has also secured the appointment of Dr.Goran Ando as Chairman of its Clinical Advisory Committee.
Dr Ando has held the position of Chairman of Novo Nordisk A /S since 2013 and has been on the board since 2005, being re-elected several times throughout his tenure. Dr Ando is a specialist in general medicine and a founding fellow of the American College of Rheumatology in the US. Dr Ando serves as chairman of the board of Symphogen A /S, Denmark and as a board member of Novo Holdings A /S, Denmark, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, and ICMEC, US. Dr Ando also serves as a Senior Advisor to Essex Woodlands Healthcare Partners, UK.
About Xeophin
Xeophin Pty Ltd is a Biotech Company with a focus on imunomodulating technologies, and is committed to the research, development and commercialisation of new and novel medical treatments, in a number of high growth therapeutic areas such as inflammation.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
